Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2287]

Weekly 20/56 mg/m² carfilzomib, lenalidomide and dexamethasone until...

Prof Xavier Leleu - Centre Hospitalier Universitaire de Lille, Lille, France

$Weekly 20/56 mg/m² carfilzomib, lenalidomide and dexamethasone until progression in early relapsed refractory multiple myeloma ( Prof Xavier Leleu - Centre Hospitalier Universitaire de Lille, Lille, France )$

Maintenance with weekly carfilzomib in elderly newly diagnosed multiple myeloma

Prof Xavier Leleu - Centre Hospitalier Universitaire de Lille, Lille, France

Maintenance with weekly carfilzomib in elderly newly diagnosed multiple myeloma ( Prof Xavier Leleu - Centre Hospitalier Universitaire de Lille, Lille, France )

Proton therapy or photon therapy as part of concurrent chemoradiotherapy for...

Prof Brian Baumann - Washington University in St. Louis, St. Louis, USA

Proton therapy or photon therapy as part of concurrent chemoradiotherapy for locally advanced cancer ( Prof Brian Baumann - Washington University in St. Louis, St. Louis, USA )

Olaparib and durvalumab in metastatic BRCA wild type triple-negative breast...

Dr Zahi Mitri - OHSU Hospital, Portland, USA

Olaparib and durvalumab in metastatic BRCA wild type triple-negative breast cancer ( Dr Zahi Mitri - OHSU Hospital, Portland, USA )

CASSIOPEIA: Daratumumab plus D-VTd vs VTd in transplant-eligible NDMM

Prof Philippe Moreau - University Hospital of Nantes, Nantes, France

CASSIOPEIA: Daratumumab plus D-VTd vs VTd in transplant-eligible NDMM ( Prof Philippe Moreau - University Hospital of Nantes, Nantes, France )

Clinical activity and tolerability of the RET inhibitor BLUE-667 in patients...

Dr Justin F. Gainor - Massachusetts General Hospital, Boston, USA

Clinical activity and tolerability of the RET inhibitor BLUE-667 in patients with advanced RET fusion and NSCLC ( Dr Justin F. Gainor - Massachusetts General Hospital, Boston, USA )

Highlights from ASCO 2019

Asst. Prof Bishal Gyawali and Monique Biryiana

Highlights from ASCO 2019 ( Asst. Prof Bishal Gyawali and Monique Biryiana )

Potential of PARP inhibitors for metastatic breast cancer

Dr Alexandra Zimmer - National Cancer Institute, Bethesda, USA

Potential of PARP inhibitors for metastatic breast cancer ( Dr Alexandra Zimmer - National Cancer Institute, Bethesda, USA )

Targeting agent enfortumab vedotin a novel treatment for patients with advanced...

Prof Daniel Petrylak - Yale Cancer Center, New Haven, USA

Targeting agent enfortumab vedotin a novel treatment for patients with advanced urothelial cancer ( Prof Daniel Petrylak - Yale Cancer Center, New Haven, USA )

New agent targeting Nectin-4 produces responses in nearly half of patients with...

Prof Daniel Petrylak - Yale Cancer Center, New Haven, USA

New agent targeting Nectin-4 produces responses in nearly half of patients with advanced urothelial cancer ( Prof Daniel Petrylak - Yale Cancer Center, New Haven, USA )

PARP inhibitor olaparib as treatment for pancreatic cancer patients with BRCA...

Dr Hedy Kindler - University of Chicago, Chicago, USA

PARP inhibitor olaparib as treatment for pancreatic cancer patients with BRCA gene mutations ( Dr Hedy Kindler - University of Chicago, Chicago, USA )

Enzalutamide as treatment for men with mHSPC who have received testosterone...

Dr Christopher Sweeney - Dana-Farber Cancer Institute, Boston, USA

Enzalutamide as treatment for men with mHSPC who have received testosterone suppression ( Dr Christopher Sweeney - Dana-Farber Cancer Institute, Boston, USA )

More from ecancer